FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 356:76-78 January 4, 2007 Number 1 Next

	Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

	Full Text PDF PDA Full Text Purchase this article Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited E-mail When Letters Appear Related Article by Chen, H.-Y. PubMed Citation

Lung cancer is the deadliest cancer in the world. Relapses are frequent after primary and adjuvant therapy and often evolve into lethal metastatic disease. Currently, lung-cancer staging rests on histopathological and clinical criteria that have only limited power to predict relapse and survival. A major effort to improve the control of lung cancer entails the use of molecular profiling to characterize tumors and provide accurate predictions of the outcome after standard or novel treatments.

Such molecular studies of lung tumors began with single or relatively small groups of potential prognostic markers and have progressed to microarray analyses of thousands of . . . [Full Text of this Article]

Source Information

From the Department of Thoracic/Head and Neck Medical Oncology, University of Texas M.D. Anderson Cancer Center, Houston.

This article has been cited by other articles:

• Herbst, R. S., Heymach, J. V., Lippman, S. M. (2008). Lung Cancer. NEJM 359: 1367-1380 [Full Text]  
• Veneziani, B. M., Criniti, V., Cavaliere, C., Corvigno, S., Nardone, A., Picarelli, S., Tortora, G., Ciardiello, F., Limite, G., De Placido, S. (2007). In vitro expansion of human breast cancer epithelial and mesenchymal stromal cells: optimization of a coculture model for personalized therapy approaches. Molecular Cancer Therapeutics 6: 3091-3100 [Abstract] [Full Text]  
• Lippman, S. M., Heymach, J. V. (2007). The Convergent Development of Molecular-Targeted Drugs for Cancer Treatment and Prevention. Clin. Cancer Res. 13: 4035-4041 [Abstract] [Full Text]